Medicare AdvantagePrior AuthMedium impact
Short Acting Beta Agonists (Revised)
Humana·Pulmonology, Emergency Medicine, Pediatrics +2 more·Medicare Advantage
Effective date
May 27, 2026
We identified it
Jun 25, 2026
Summary
Humana Medicare Advantage has revised its Short Acting Beta Agonist (SABA) inhaler coverage policy, effective May 27, 2026. The policy implements step therapy requiring members to have prior treatment with generic albuterol HFA or Ventolin HFA before coverage of branded alternatives (ProAir RespiClick, ProAir Digihaler, Xopenex HFA, levalbuterol HFA). This is a prior authorization requirement that affects pharmacy claims for these specific SABA inhalers.
Action Required
By May 27, 2026: Billing team must implement step therapy verification in pharmacy claim processing systems for all SABA inhaler claims. Specifically: (1) Verify that members have documented prior treatment with generic albuterol HFA or Ventolin HFA before approving/billing ProAir RespiClick, ProAir Digihaler, Xopenex HFA, or levalbuterol HFA for Humana Medicare Advantage members; (2) Update pharmacy system to flag these branded SABA inhalers for prior authorization review; (3) Train billing and pharmacy staff on the step therapy requirement; (4) Notify prescribers of the policy change to prevent claim denials. Claims submitted without evidence of prior generic albuterol treatment will be denied. Coordinate with pharmacy department and providers to avoid patient access delays.